Dr Jesus Acebillo, former CEO of Novartis Spain and president of Farmaindustria, has joined the investment committee for the Inveready Biotech III fund. This is Inveready’s third vehicle specialising in the life sciences. The fund was set up this year with the aim of investing in 20 biotechnology companies.
“Inveready has been making a decisive contribution to the development of the biotechnology sector in our country for years now. It is an honour to be part of the expansion and consolidation of this activity,” said Jesus Acebillo.
“Jesus Acebillo’s experience and network of contacts is a very valuable asset that we will apply both in selecting companies and in supporting them once the investment has been made,” explains Sara Secall, partner and director of Investment in the Life Sciences at Inveready.
Comments